And the Finalists Are… Meet Your BioHealth Capital Region 2023 Annual Awards Finalists

Published on : Published by : BioBuzz Media

We are thrilled to announce the finalists for BioBuzz’s 2023 Annual Awards for the BioHealth Capital Region (Maryland, Washington, DC, Virginia).

Veralox, McBee Moore & Vanik IP, LLC and the Importance of Patent Protection

Published on : Published by : Alex Keown

Intellectual property is the lifeblood of biopharmaceutical companies. Protection of that information is of paramount importance and it is one reason companies seek legal firms that specialize in intellectual property and patent protection.

Veralox Therapeutics Appoints Michael Hanna As Chief Medical Officer

Published on : Published by : BioBuzz Media

Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced the appointment of Michael S. Hanna, MD, FACC, as chief medical officer.

Veralox Therapeutics Announces Closing Of $16.6 Million Series A Financing And Announces New Board Members

Published on : Published by : BioBuzz Media

Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced the closing of a $16.6 million Series A financing. The round was led by Hatteras Venture Partners with participation from Genesys Capital, Point Field Partners and Alexandria Venture Investments as well as support from previous Veralox investors including Sanofi Ventures, JDRF T1D Fund, Maryland Momentum Fund, VTC Innovation Fund and TEDCO. The Company also announced that Ben Scruggs, PhD, principal at Hatteras Venture Partners, and Jamie Stiff, MBA, managing director at Genesys Capital, will join the Veralox Therapeutics board of directors.

Veralox Therapeutics Announces IND Submission for VLX-1005 to Treat Heparin-Inducted Thrombocytopenia

Published on : Published by : BioBuzz Media

Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced it submitted an Investigational New Drug  (IND) application with the U.S. Food and Drug Administration (FDA) for initiation of a Phase 1 clinical trial of VLX-1005, a first-in-class small molecule inhibitor of 12-Lipoxygenase in development for the treatment of heparin-induced thrombocytopenia (HIT).